Taisho Pharmaceutical Holdings Co., Ltd.
4581
Rank in Stocks
#3722
Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise... Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise involved in the comprehensive research, development, production, marketing, and distribution of both non-prescription (OTC) and ethical pharmaceutical products, serving markets in Japan and worldwide. The company's operations are divided into two principal divisions: the Self-Medication Operation Group and the Prescription Pharmaceutical Operation Group. The Self-Medication Group provides a diverse portfolio of consumer health products, including over-the-counter medicines, quasi-pharmaceuticals, food products, and general medical and hygiene items. Prominent brands within this segment include the Lipovitan energy drink series, Pabron cold and sinus remedies, RiUP hair re-growth solutions, Taisho Kampo gastrointestinal treatments, Colac laxatives, Naron and other pain relievers for fever, Preser hemorrhoid treatments, Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic-analgesic relief, Counterpain topical anti-inflammatory products, Vitacilina dermatological treatments, and VICKS cough suppressant throat lozenges and medicated drops. This division also encompasses real estate leasing, facility management, and hotel operations. Conversely, the Prescription Pharmaceutical Group specializes in ethical drugs such as Edirol, an active vitamin D3 agent for osteoporosis; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate for osteoporosis; Lusefi, an agent for type 2 diabetes mellitus; and LOQOA, a transdermal anti-inflammatory analgesic. This segment is also engaged in ongoing drug development, primarily focusing on therapeutic areas like central nervous system disorders, infectious diseases, metabolic conditions, and orthopedic ailments. Additionally, Taisho Pharmaceutical Holdings supplies raw materials for pharmaceutical and quasi-drug manufacturing, alongside offering health foods and skincare products. The company was established in Tokyo, Japan, in 1912, where its headquarters remain.
Share Price
$54.31
Last synced: 2024-04-08
Market Cap
$4.45B
Change (1 day)
-4.14%
Change (1 year)
0.00%
Country
JP
Trade Taisho Pharmaceutical Holdings Co., Ltd. (4581)
Category
Healthcare
P/E ratio for Taisho Pharmaceutical Holdings Co., Ltd. (4581)
P/E ratio as of 2026 TTM: 0
According to Taisho Pharmaceutical Holdings Co., Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Taisho Pharmaceutical Holdings Co., Ltd. from 2006 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2023 | 23.82 | -32.43% |
| 2022 | 35.25 | -17.63% |
| 2021 | 42.80 | 62.90% |
| 2020 | 26.27 | 48.79% |
| 2019 | 17.66 | -33.06% |
| 2018 | 26.38 | 5.10% |
| 2017 | 25.10 | -21.85% |
| 2016 | 32.12 | 8.69% |
| 2015 | 29.55 | 43.36% |
| 2014 | 20.61 | 4.59% |
| 2013 | 19.71 | -13.01% |
| 2012 | 22.65 | 39.72% |
| 2011 | 16.21 | -45.57% |
| 2010 | 29.79 | -55.85% |
| 2009 | 67.48 | 179.91% |
| 2008 | 24.11 | -39.88% |
| 2007 | 40.10 | 130.50% |
| 2006 | 17.39 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | - |
IN
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.